Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series
Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone’s generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS.
KeywordsWilliams syndrome Anxiety Buspirone
This work was funded by the Nancy Lurie Marks Family Foundation.
RPT, CJK and CJM drafted the manuscript. CJM performed the ratings of the Pediatric Anxiety Rating Scale with the mother of each subject. RPT, CJK, JLW, BRP and CJM reviewed the final version of the manuscript and gave approval for its submission.
Compliance with Ethical Standards
Conflict of interest
Drs. Thom, Pober and McDougle and Ms. Waxler declare that they have no conflicts of interest. Dr. Keary has been a compensated consultant, served on a scientific advisory board and received research support from Ovid Therapeutics.
Informed consent was obtained from the legal guardian of all individual participants included in the study.
Research Involving Human Participants and/or Animals
The study was granted exemption from requiring ethics approval by the Partners Human Research Committee Institutional Review Board because the number of subjects included in the study is less than four.
- Bergman, J., Roof, R. A., Furman, C. A., Conroy, J. L., Mello, N. K., Sibley, D. R., et al. (2013). Modification of cocaine self-administration by buspirone (buspar®): Potential involvement of D3 and D4 dopamine receptors. International Journal of Neuropsychopharmacology,16(2), 445–458. https://doi.org/10.1017/S1461145712000661.CrossRefPubMedGoogle Scholar
- Ceranoglu, T. A., Wozniak, J., Fried, R., Galdo, M., Hoskova, B., Fong, M. D., et al. (2018). A retrospective chart review of buspirone for the treatment of anxiety in psychiatrically referred youth with high-functioning autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2018.0021.CrossRefPubMedGoogle Scholar
- Chugani, D. C., Chugani, H. T., Wiznitzer, M., Parikh, S., Evans, P. A., Hansen, R. L., et al. (2016). Efficacy of low-dose buspirone for restricted and repetitive behavior in young children with autism spectrum disorder: A randomized trial. The Journal of Pediatrics,170(45–53), e1–e4. https://doi.org/10.1016/j.jpeds.2015.11.033.CrossRefGoogle Scholar
- Leyfer, O. T., Woodruff-Borden, J., Klein-Tasman, B. P., Fricke, J. S., & Mervis, C. B. (2006). Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics,141B(6), 615–622. https://doi.org/10.1002/ajmg.b.30344.CrossRefGoogle Scholar
- Martens, M. A., Seyfer, D. L., Andridge, R. R., Foster, J. E. A., Chowdhury, M., McClure, K. E., et al. (2012). Parent report of antidepressant, anxiolytic, and antipsychotic medication use in individuals with Williams syndrome: Effectiveness and adverse effects. Research in Developmental Disabilities,33(6), 2106–2121. https://doi.org/10.1016/j.ridd.2012.06.006.CrossRefPubMedGoogle Scholar
- Martens, M. A., Wilson, S. J., & Reutens, D. C. (2008). Research Review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype. Journal of Child Psychology and Psychiatry,49(6), 576–608. https://doi.org/10.1111/j.1469-7610.2008.01887.x.CrossRefPubMedGoogle Scholar
- Morris, C. A. (1993). Williams Syndrome. GeneReviews ®. Retrieved January 23, 2019, from http://www.ncbi.nlm.nih.gov/pubmed/20301427.
- Royston, R., Howlin, P., Waite, J., & Oliver, C. (2017). Anxiety disorders in Williams syndrome contrasted with intellectual disability and the general population: A systematic review and meta-analysis. Journal of Autism and Developmental Disorders,47(12), 3765–3777. https://doi.org/10.1007/s10803-016-2909-z.CrossRefPubMedGoogle Scholar
- Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., et al. (2017). Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Therapeutics and Clinical Risk Management,13, 757–777. https://doi.org/10.2147/TCRM.S117321.CrossRefPubMedPubMedCentralGoogle Scholar
- The Pediatric Anxiety Rating Scale (PARS): Development and psychometric properties. (2002). Journal of the American Academy of Child and Adolescent Psychiatry, 41(9), 1061–1069. Retrieved August 19, 2019, from http://www.ncbi.nlm.nih.gov/pubmed/12218427.
- Woodruff-Borden, J., Kistler, D. J., Henderson, D. R., Crawford, N. A., & Mervis, C. B. (2010). Longitudinal course of anxiety in children and adolescents with Williams syndrome. American Journal of Medical Genetics Part C: Seminars in Medical Genetics,154C(2), 277–290. https://doi.org/10.1002/ajmg.c.30259.CrossRefGoogle Scholar